Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Pediatrics

Pediatrics

                        FDA Perspectives on Pediatric Health
          Pediatric Medical Product Safety
          Pediatric Ethics
          International Collaboration / Pediatric Cluster
          Pediatric Science and Research Activities
          Medical Products for Newborns
          Pediatric Labeling Changes
          Reports, Statistics, Reviews and Databases Home
          Science & Research
          Science and Research Special Topics
          Pediatrics
          International Collaboration / Pediatric ClusterPediatrics International Collaboration / Pediatric Cluster
  
  	
    Share
    Post
    Linkedin

    Email
    PrintThe FDA is engaged in international collaborative exchanges related to pediatrics.  The objective of these exchanges is to ensure that pediatric studies are conducted in a scientifically rigorous and ethical manner and that pediatric patients are not exposed to unnecessary (e.g., duplicative) trials. Pediatric legislation in the U.S. and Europe is driving pediatric product development on a global scale.



**Pediatric Cluster**

In August 2007, EMA and FDA established monthly teleconferences between regulators called the Pediatric Cluster to discuss product-specific pediatric development and topics related to product classes under the terms of Confidentiality Agreement. The objective of these exchanges are to enhance the science of pediatric trials and to avoid exposing children to unnecessary trials. This collaboration provides a robust ethical and scientific framework for pediatric studies. The teleconferences are held monthly but there may be additional meetings to accommodate timelines.

Japan's PMDA joined these teleconferences in November 2009 and Health Canada in September 2010 as observers. They are now active participants in these monthly exchanges. Australia's Therapeutic Goods Administration joined the teleconferences in January 2014 and they are now active participants in these exchanges.

The monthly discussions include ethical, safety, and pediatric study feasibility issues as well as protocol discussions. The type of information exchanged includes:

Pediatric Investigation Plans (PIPs);
	Written Requests;
	Pediatric Committee (PDCO) discussions;
	waivers and deferrals;
	choice of comparator and efficacy endpoints;
	status of ongoing pediatric studies; results of pediatric studies;
	safety concerns, including clinical holds;
	plans for long-term safety monitoring.In July 2018, we started a new process with our Pediatric Cluster teleconference. We share high level action items with the sponsor of products following discussion at the Pediatric Cluster. The objective is to let sponsors know that their product was discussed and the agreed upon action.



Common Commentary

The Common Commentary is a tool to inform sponsors of products discussed at the Pediatric Cluster. The document provides informal, non-binding comments to sponsors on pediatric development plans that have been submitted to both FDA and EMA, which are under review by both agencies and have been discussed at the Pediatric Cluster.

SOP for Common Commentary
	Common Commentary for submission of iPSPs and PIPs for COVID-19 (PDF- 271KB)
	Gaucher Disease Common Commentary
	Common Commentary Statistic
	Common Commentary for EMA and FDA Scientific Review of Pediatric Cancer Drug Development ProgramsRelated Links

European Medicines Agency (EMA)

                                                                                  Content current as of:
      07/03/2023Pediatrics

          
                        FDA Perspectives on Pediatric Health
          Pediatric Medical Product Safety
          Pediatric Ethics
          International Collaboration / Pediatric Cluster
          Pediatric Science and Research Activities
          Medical Products for Newborns
          Pediatric Labeling Changes
          Reports, Statistics, Reviews and Databases
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop